These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
153 related items for PubMed ID: 3549123
1. C-peptide in diabetes mellitus treated with insulin. A 3-year epidemiological study on the island of Falster, Denmark. Nielsen NV, Tronier B. Diabetes Res; 1986 Nov; 3(9):475-8. PubMed ID: 3549123 [Abstract] [Full Text] [Related]
3. Prevalence of diabetes mellitus treated with insulin and oral hypoglycemic agents in Denmark. Nielsen NV, Hemmingsen L. Diabetes Res; 1986 Oct; 3(8):423-5. PubMed ID: 3545623 [Abstract] [Full Text] [Related]
4. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab; 1987 Jul; 65(1):30-6. PubMed ID: 2884229 [Abstract] [Full Text] [Related]
5. Plasma C-peptide concentration in women with Type 1 diabetes during early and late pregnancy. Murphy HR, Elleri D, Allen JM, Simmons D, Nodale M, Hovorka R. Diabet Med; 2012 Oct; 29(10):e361-4. PubMed ID: 22804483 [Abstract] [Full Text] [Related]
6. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr. Snorgaard O, Lassen LH, Binder C. Diabetes Care; 1992 Aug; 15(8):1009-13. PubMed ID: 1505301 [Abstract] [Full Text] [Related]
7. More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity. Kabadi UM, McCoy S, Birkenholz M, Kabadi M. Diabet Med; 1995 Oct; 12(10):880-4. PubMed ID: 8846678 [Abstract] [Full Text] [Related]
8. Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Törn C, Landin-Olsson M, Ostman J, Scherstén B, Arnqvist H, Blohmé G, Björk E, Bolinder J, Eriksson J, Littorin B, Nyström L, Sundkvist G, Lernmark A. Diabetes Metab Res Rev; 2000 Oct; 16(6):442-47. PubMed ID: 11114103 [Abstract] [Full Text] [Related]
9. [C-peptide determination in diabetics for the evaluation of insulin requirements]. Keller U, Pasquel M, Berger W. Schweiz Med Wochenschr; 1987 Feb 07; 117(6):187-92. PubMed ID: 3551060 [Abstract] [Full Text] [Related]
10. Prevalence of fasting hyperglycemia and known non-insulin-dependent diabetes mellitus classified by plasma C-peptide: Fredericia survey of subjects 60-74 yr old. Damsgaard EM, Faber OK, Frøland A, Green A, Hauge M, Holm NV, Iversen S. Diabetes Care; 1987 Feb 07; 10(1):26-32. PubMed ID: 3552511 [Abstract] [Full Text] [Related]
11. Comparative study of insulin antibodies in diabetic patients with primary insulin-dependence (type I) and secondary insulin-dependence (type II). Ionescu-Tîrgovişte C, Mirodon Z, Cheţa D, Sântu E, Simionescu M, Nicolau A, Mincu I. Med Interne; 1989 Feb 07; 27(4):303-11. PubMed ID: 2694321 [Abstract] [Full Text] [Related]
12. Metabolic effect of islet B-cell function in insulin-treated diabetes. Gjessing HJ, Matzen LE, Iversen S, Faber OK, Frøland A. Scand J Clin Lab Invest; 1989 Jun 07; 49(4):337-43. PubMed ID: 2662383 [Abstract] [Full Text] [Related]
13. Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas. Wolffenbuttel BH, Weber RF, Weeks L, van Koetsveld PM, Verschoor L. Diabetes Res; 1990 Feb 07; 13(2):79-84. PubMed ID: 2091874 [Abstract] [Full Text] [Related]
14. Classifying diabetes according to the new WHO clinical stages. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD. Eur J Epidemiol; 2001 Feb 07; 17(11):983-9. PubMed ID: 12380709 [Abstract] [Full Text] [Related]
15. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Diabetes Care; 1993 Jun 07; 16(6):902-10. PubMed ID: 8325204 [Abstract] [Full Text] [Related]
16. Serum C-peptide concentrations and their value in evaluating the usefulness of insulin therapy in elderly diabetics. Kyllästinen M, Elfving S. Gerontology; 1986 Jun 07; 32(6):317-26. PubMed ID: 3556328 [Abstract] [Full Text] [Related]
17. Factors associated with fasting and postglucagon plasma C-peptide levels in middle-aged insulin-treated diabetic patients. Laakso M, Rönnemaa T, Sarlund H, Pyörälä K, Kallio V. Diabetes Care; 1989 Feb 07; 12(2):83-8. PubMed ID: 2649329 [Abstract] [Full Text] [Related]
18. Prevalence of macro- and microvascular disease as related to glycosylated hemoglobin in type I and II diabetic subjects. An epidemiologic study in Denmark. Nielsen NV, Ditzel J. Horm Metab Res Suppl; 1985 Feb 07; 15():19-23. PubMed ID: 3908278 [Abstract] [Full Text] [Related]
19. The KID Study. III: Impact of inpatient rehabilitation on the metabolic control of type I and type II diabetics--a one-year follow-up. Haupt E, Herrmann R, Benecke-Timp A, Vogel H, Hilgenfeldt J, Haupt A, Walter C. Exp Clin Endocrinol Diabetes; 1996 Feb 07; 104(6):420-30. PubMed ID: 9021342 [Abstract] [Full Text] [Related]
20. Circadian variations in plasma immunoreactive insulin (IRI) and C-peptide concentrations in adult onset (type II) diabetes mellitus. Nicolau GY, Haus E, Lakatua DJ, Bogdan C, Petrescu E, Sackett-Lundeen L, Stelea S, Stelea P. Endocrinologie; 1984 Feb 07; 22(1):3-16. PubMed ID: 6369501 [Abstract] [Full Text] [Related] Page: [Next] [New Search]